The Carlyle Group to invest in Orifarm Group.

The Carlyle Group, an American multinational company with operations in private equity, alternative asset management and financial services, agreed to invest in Orifarm Group, one of the largest European suppliers of parallel imported and generic pharmaceuticals. Financial terms were not disclosed. "This strategic investment will significantly enhance our ability to capitalise on the attractive opportunities, both organic and inorganic, that we positioned Orifarm for following the transformational asset deal with Takeda in 2020. We are confident that this marks the start of an exciting future for the business, our employees, and other stakeholders," Erik Sandberg, Orifarm Group CEO.